EN
Home/Start here/A few pounds, or before an event
Reading path3 guides, in order

I want to lose a few pounds before an event. Should I try a GLP-1?

An honest answer for anyone eyeing a weight-loss injection before a wedding, a holiday or a big day.

The short answer

Probably not. In the UK, GLP-1 medicines are licensed for type 2 diabetes, and for obesity or overweight with a related health problem, not for a few pounds. The MHRA, the UK medicines regulator, says they shouldn't be used to lose weight for cosmetic reasons. They take months to reach full dose, often upset the stomach, and the weight usually returns when you stop. There are better ways to feel good on the day.

Read this page first. It covers why these medicines aren't meant for a few pounds, what happens after, the fakes and what works instead. At the end, three guides take you further, in order.
On this page
  1. Why it isn't meant for this
  2. Would it work in time?
  3. After the event
  4. The fakes problem
  5. What works instead
  6. What to read next
  7. Sources

Why isn't it meant for this?

These medicines treat a disease. They aren't meant for fine-tuning your weight.

Wanting to look and feel your best on a big day is completely normal. But the MHRA says GLP-1 medicines should only be used if you are overweight or have diabetes, "and not if you want to lose weight for aesthetic or cosmetic purposes".2

Here are the lines that matter in the UK:

  • The licence. Wegovy and Mounjaro are licensed for weight management in adults with a BMI (body mass index, your weight compared with your height) of 30 or more, or 27 to under 30 with at least one weight-related health problem, such as high blood pressure.3
  • NICE's healthy range. NICE, which writes guidance for the NHS in England, counts a BMI of 18.5 to 24.9 as healthy. Overweight starts at 25, or at 23 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.4
  • The NHS. NHS access is far narrower than the licence. In England, GPs prescribe Mounjaro for weight first to people with a BMI of 40 or more and several weight-related conditions.11
  • Ozempic. In the UK it is licensed for type 2 diabetes only, not for weight loss.2

So if you're in the healthy range, or just above it, these medicines aren't licensed for you.

Would it even work in time?

Not really. The dose goes up slowly, over about 4 months.

Wegovy starts at 0.25 mg and steps up every 4 weeks. It reaches the full dose of 2.4 mg after 16 weeks.1

Feeling sick and diarrhoea were the most common side effects in STEP 1, the main semaglutide weight trial. People there got either the medicine or a dummy injection with no medicine in it. More people stopped because of stomach effects on the medicine.5

Out of every 100 people, how many stopped because of stomach effects:

STEP 1Semaglutide 2.4 mg (Wegovy), weekly

1,961 adults with obesity or overweight and no diabetes, 68 weeks.5

Semaglutide4.5 in 100
Dummy injection0.8 in 100

Bars are drawn on a scale up to 10 in 100.

Not ideal in the weeks before a celebration. The MHRA also reminds people that these medicines are not a quick way to lose weight.2

What happens after the event?

The weight usually comes back once you stop.

A year after stopping semaglutide, people followed up from STEP 1 had regained about two-thirds of the weight they lost.6 Most of their gains in blood pressure, sugar and cholesterol faded too.6

What about the fakes?

Fake pens exist in the UK. Buying without a proper consultation, from unregulated sellers, raises the risk of getting one.

  • The WHO has found falsified Ozempic in Brazil, the UK and the US. Fakes may be missing the medicine, or contain a different one, such as insulin.12
  • The MHRA has warned about fake Ozempic and Saxenda pens found in the UK.8 In February 2026 a falsified Mounjaro 15 mg pen was supplied through a UK online pharmacy.7
  • The MHRA says never to buy from beauty salons or social media, and that powders in vials you mix yourself are not authorised.2
Get help now. If you've injected a pen of unknown origin and feel shaky, confused or faint, call 999.

So what works instead?

A plan built around food and movement, started as early as you can.

The WHO says medicines alone won't solve weight problems. Healthy eating and physical activity remain the base of treatment.9 Guide 3: Your options sets out what the evidence says about each option.

And if your weight is affecting your health, that's a different conversation. Guide 1: Weight and health helps you check where you stand.

What to read next, in order

These three guides go deeper. Each one ends with a link to the next, so you can read them one after another.

  1. 1Should I consider a GLP-1? And when not toGuide 4 of 9DecideThe section on losing a few pounds: who these medicines are for, and who they're not for.
  2. 2Your options, and where medicines fitGuide 3 of 9DecideFood, activity and other options, with what the evidence says about each.
  3. 3Stopping and the long termGuide 9 of 9Live with itWhat happens to weight, and to your body, when people stop.
Was this page easy to understand?

Sources

  1. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. Sections 1, 2.2, 5.2, 5.3, 5.5, 8.3, 17. (US label.) PDF
  2. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK, updated 5 February 2026. Licensed-use table, where to find GLP-1 medicines, pregnancy, and summary. Link
  3. Novo Nordisk. Wegovy 2.4 mg FlexTouch, UK summary of product characteristics (SmPC), section 4.1; Eli Lilly, Mounjaro KwikPen UK SmPC, section 4.1. Electronic Medicines Compendium. Wegovy · Mounjaro
  4. NICE. Overweight and obesity management. NICE guideline NG246, updated 8 January 2026. Recommendations 1.9.10 and 1.9.11. Link
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021;384:989–1002. 1,961 adults without diabetes, 68 weeks. DOI
  6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. 327 people followed for a year after stopping. DOI
  7. MHRA. Drug Safety Update: falsified Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens. 24 February 2026. Link
  8. MHRA. MHRA warns of unsafe fake weight loss pens. GOV.UK, 26 October 2023. Link
  9. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. 1 December 2025. Link
  10. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised May 2026. Sections 4, 5.3, 5.5, 5.6, 7.2, 8.5. (US label.) PDF
  11. NICE. Tirzepatide for managing overweight and obesity. Technology appraisal TA1026, "What this means in practice" (phased groups in England). Link
  12. World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss. 20 June 2024. Link

Last checked 12 Oct 2026 · Next review due Jan 2027

How this page was made. Written by the GLP Guidebook team from the sources above: drug labels, published trials, NICE and international guidelines, and official MHRA pages. It's general information, not medical advice. Talk to your GP or another qualified prescriber before starting, stopping or changing any medicine. How we write